Long-term treatment of Parkinson's disease with bromocriptine.
AUTOR(ES)
Rascol, A
RESUMO
BRomocriptine (15-75 mg per day) alone or with L-dopa was studied during five to 29 months on 44 patients with Parkinson's disease. Used as sole therapeutic agent, it was found excellent in 12 patients who had never received regular L-dopa treatment either because it was never attempted or because of intolerance from the outset. Its anti-Parkinsonism activity was comparable with L-dopa. The gain was stable in the long term until this report. The side effects of L-dopa were not seen after bromocriptine. In cases where L-dopa had ceased to be active, bromocriptine produced a further improvement if mental deterioration was not associated. In very advanced forms of Parkinson's disease with associated dementia, bromocriptine did not produce durable results. Bromocriptine did not improve the "on-off" effects but reduced a number of the side effects of L-dopa, in particular cardiac, painful contractions, and dyskinesia without "on-off" effects.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=490179Documentos Relacionados
- Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.
- Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
- Bromocriptine treatment in Parkinson's disease.
- Influence of dystonia on the response to long-term L-dopa therapy in Parkinson's disease
- Long-term treatment of multiple sclerosis with azathioprine